Abstract: According to the present invention, a cured product obtained by curing a curable composition including a compound represented by General Formula 1, in which a birefringence ?n (587 nm) is 0.00??n (587 nm)?0.01, is provided, and this cured product is suitable for manufacturing an optical member. Pol1-Sp1-L1-Ar-L2-Sp2-Pol2??(General Formula 1) In formula, Ar is an aromatic ring group represented by General Formula 2-2 and the like. In formula, Z1 and Z2 each represent a hydrogen atom, a methyl group, and the like; A1 and A2 each represent —S— and the like; X represents C(Rz)2 and the like (where Rz is a substituent, and two Rz's may form a ring); L1 and L2 each represent a single bond, —O—, —OC(?O)—, —OC(?O)O—, —OC(?O)NH—, and the like; Sp1 and Sp2 each represent a single bond or a divalent linking group; Pol1 and Pol2 each represent a hydrogen atom or a polymerizable group; and a compound represented by General Formula 1 has at least one polymerizable group.

Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.

Abstract: This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H2S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.

Abstract: The present invention relates to processes for making cabazitaxel, cabazitaxel analogues and intermediates thereof. The invention provides novel compounds useful in the synthesis of cabazitaxel.

Abstract: The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction.

Abstract: The present invention relates to processes for making cabazitaxel, cabazitaxel analogues and intermediates thereof. The invention provides novel compounds useful in the synthesis of cabazitaxel.

Abstract: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.

Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Abstract: A radically polymerizable compound having a group represented by formula (1) (In the formula, R1 to R3 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, X represents an alkylene group having 1 to 4 carbon atoms.) and a radically polymerizable double bond and a composition for an optical material comprising the same have a high refractive index and excellent transparency and are hard to be oxidized in thermal curing and useful as an optical material with little tinting.

Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Abstract: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.

Abstract: The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.

Abstract: A radically polymerizable compound having a group represented by formula (1) (In the formula, R1 to R3 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, X represents an alkylene group having 1 to 4 carbon atoms.) and a radically polymerizable double bond and a composition for an optical material comprising the same have a high refractive index and excellent transparency and are hard to be oxidized in thermal curing and useful as an optical material with little tinting.

Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Abstract: Cosmetic and therapeutic, in particular dermatological bioprecursors have the formula [A]n—PP—[B]m wherein PP is a polyphenol radical in which each hydroxyl function is protected by a group A or a group B, A is a saturated or unsaturated, substituted or unsubstituted alkyl radical having 1 to 20 carbon atoms which is bonded to the polyphenol, n is an integer not less than 1, and B is a precursor of a biologically active molecule, which is also bonded to the polyphenol, and m is an integer also not less than 1.

Abstract: Compounds of general formula: wherein R?, R, x and z have the meaning reported in the specification, are useful for treating inflammatory diseases including metabolic syndrome, diabetes, obesity, dyslipidemia, and insulin resistance.

Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A compound having a formula selected from the group consisting of wherein the substituents are as defined in the specification. The compounds are useful as intermediates in the preparation of compounds of formula (I), which are useful for inhibiting NO synthase and regenerate antioxidants.

Abstract: Disclosed herein are a gelling agent composed of a functional amino acid compound having a tetrathiafulvalenyl group, and a production method of a gelling agent, comprising reacting a tetrathiafulvalene derivative with an amino acid derivative in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-(N,N-dimethylamino)pyridine to obtain a functional amino acid compound having a tetrathiafulvalenyl group.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: The invention relates to novel methylene-dioxybenzenes comprising at least one cationic group Z, Z being chosen from quaternized aliphatic chains, aliphatic chains comprising at least one quaternized saturated ring and aliphatic chains comprising at least one quaternized unsaturated ring, to their use as oxidation dye precursors for the oxidation dyeing of keratin fibres, to dye compositions containing them and to oxidation dyeing processes using them.

Abstract: The present invention provides a compound containing at least one sulfhydryl group and at least one NO donor group, wherein said compound is a) a compound containing one or more sulfhydryl groups linked to at least one aromatic ring or a heteroaromatic ring with a nitrogen in the ring structure, which ring is substituted by one or more substituents bearing a terminal —ONO2 group; b) a 5-membered ring heterocyclic compound containing a sulfur atom and a nitrogen atom, which ring is substituted by one or more substituents bearing a terminal —ONO2 group; c) a 5-membered ring compound containing two conjugate S-atoms, which ring is linked to one or more substituents bearing a terminal—ONO2 group; or d) a compound containing an acyclic —S—S group, linked to at least one aromatic ring or a heteroaromatic ring with a nitrogen in the ring structure, which ring is substituted by one or more substituents bearing a terminal —ONO2 group.

Abstract: Polymerizable compositions from novel monomers that correspond to the formula: in which: Z represents H or CH3 and X represents O or S, and Y is a 5- to 8-membered heterocycle consisting of hydrogen, carbon and sulphur atoms and at least two endocyclic sulphur atoms.

Abstract: The novel monomers correspond to the formula: in which: Z represents H or CH3 and X represents O or S, and Y is a 5- to 8-membered heterocycle consisting of hydrogen, carbon and sulphur atoms and at least two endocyclic sulphur atoms.

Abstract: The present invention is directed to pharmaceutical compositions including a saturated 1,2-dithiaheterocyclic compound having antiviral activity. The present invention also provides a kit containing the pharmaceutical composition and methods of treating or preventing viral disease using the composition, as well as methods for inactivating retrovirus in a body fluid.

Abstract: Nucleotide analogues having the general formula (I) and pharmaceutically acceptable derivatives: ##STR1## wherein n is 0 or an integer; X is O or S, CH.sub.2, CH-halogen, CH--N.sub.3, or C.dbd.CH.sub.2 ;Q and U are independently selected from: O, S, and CH(R.sub.a) wherein R.sub.a is hydrogen, OH, halogen, N.sub.3, NH.sub.2, SH, carboxyl, C.sub.1-6 alkyl or R.sub.a is CH.sub.2 (R.sub.b) wherein R.sub.b is hydrogen, OH, SH, NH.sub.2, C.sub.1-6 alkyl or carboxyl; or both Q and U are CH when Q and U are linked by a double bond;Z is selected from: O, a C.sub.1-6 alkoxy, a C.sub.1-6 thioalkyl, a C.sub.1-6 aminoalkyl, (CH.sub.2).sub.m wherein m is 0 or an integer, and N(R.sub.c).sub.2 wherein both R.sub.c are independently hydrogen or a C.sub.1-6, alkyl; andR2 is a purine or pyrimidine base or an analogue or derivative thereof are disclosed. Members of this series of analogues possess anti-viral activity.

Abstract: Nonlinear optical compounds which contain a heteroaromatic ring and may further comprise a tricyanovinyl group attached to the heteroaromatic ring.

Abstract: Disclosed are (2-one (or thione)-1,3-dithiole-4,5-diyl)bis(thiomethylthiocyanate) compounds corresponding to the formula: ##STR1## wherein Z is oxygen or sulfur, compositions containing said compounds and their use as antimicrobial and marine antifouling agents.

Abstract: Disclosed is (2-thione-1,3-dithiole 4,5-diyl) bis(thiocyanate), its preparation and its use as an antimicrobial and marine antifouling agent.

Abstract: 2,4-Diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to therapeutic compositions based on compounds chosen from the formulae: ##STR1## in which: X is chosen from .dbd.S, .dbd.O, .dbd.SO, .dbd.N--OH, .dbd.N--R.sub.5, .dbd.N--NH--CONH.sub.2, .dbd.N--NH--CSNH.sub.2 and ##STR2## A is chosen from the ##STR3## group, a group of formula ##STR4## a C.dbd.O group, a group C.dbd.N--R.sub.4 and a CHOH group, and their pharmaceutically acceptable salts.These compositions may be used as free-radical trapping agents.

Abstract: Water-soluble 1,2-dithiole-3-thione derivatives are prepared by reacting a polyoxyalkylated starting material with sulfur. These derivatives are useful as corrosion inhibitors, particularly in aqueous environments.

Abstract: Cyclohexenone oxime ethers ##STR1## where R.sup.1 is alkyl;A is substituted or unsubstituted alkylene or alkenylene, where methylene is replaced by an oxygen atom, a sulfur atom, a sulfoxyl group, a sulfonyl group or --NR.sup.a --,Z is phenyl or a 5- or 6-membered heteroaromatic structure;X is substituted or unsubstituted amino, nitro, cyano, halogen, alkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkylthio, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -haloalkoxy, carboxyl, C.sub.1 -C.sub.4 -alkoxycarbonyl, substituted or unsubstituted benzyloxycarbony or phenyl;n is 0 to 3, or 1 to 5 where X is halogen;R.sup.

Abstract: The use of 5-phenyl-3H-1,2-dithiol-3-thion-S-oxides which are optionally substituted in the phenyl ring as active substances in hepato-protective medicaments and new 5-phenyl-3H-1,2-dithiol-3-thion-S-oxides which are substituted in the phenyl ring are described.

Abstract: Compounds of the formula I ##STR1## in which X.sub.1, X.sub.2 and X.sub.3, independently of one another, are S or Se, R.sub.1 and R.sub.2, independently of one another, are H, linear or branched C.sub.1 -C.sub.18 alkyl-X.sub.4 - or R.sub.1 and R.sub.2 together are ##STR2## in which X.sub.4 is S or Se, z is 0 and n is an integer from 2 to 6 or z is 1 and n is an integer from 1 to 4, R.sub.4 and R.sub.5, independently of one another, are H or C.sub.1 -C.sub.6 alkyl, and R.sub.3 is linear or branched C.sub.1 -C.sub.12 alkyl or phenyl.The compounds can be converted into unsymmetrically substituted chalcogenofulvalenes, from which electrically conducting charge-transfer complex salts can be prepared.

Abstract: Water-soluble 1,2-dithiole-3-thione derivatives are prepared by reacting a polyoxyalkylated starting material with sulfur. These derivatives are useful as corrosion inhibitors, particularly in aqueous environments.

Abstract: The invention pertains to organic compounds of the tetrahiafulvalene type made amphiphillic by substitution of the radicals R.sup.1 and R.sup.2 meeting one of the following conditions:R.sup.1 is a hydrophilic group and R.sup.2 is a hydrophobic group,R.sup.1 is a hydrophobic group and R.sup.2 is a hydrophilic group,R.sup.1 is an aromatic group and R.sup.2 is a group having a long carbon-containing chain with a hydrophobic nature and a hydrophilic end.These organic compounds can form Langmuir-Blodgett films which are made anisotropically conductive by doping.

Abstract: Disclosed is a novel inosose compound represented by the general formula: ##STR1## wherein X.sup.1 and X.sup.2 are both halogen; X.sup.1 is hydrogen and X.sup.2 is halogen; or X.sup.1 is --SQ.sup.1 and X.sup.2 is --SQ.sup.2 (each of Q.sup.1 and Q.sup.2 is lower alkyl or Q.sup.1 and Q.sup.2 may form lower alkylene), R.sup.1 is a protective group for hydroxyl and Y is .dbd.O, .dbd.N--Z (Z is hydroxyl which may be protected) or ##STR2## (A is hydrogen or an amine residue), particularly to the compound wherein the symbol Y is oxygen.The inosose compound is useful as intermediates for production of valiolamine and the N-substituted derivatives thereof, which have potent .alpha.-glucosidase inhibiting activities and are useful as preventives or therapeutics for symptoms of hyperglycemia and various diseases derived therefrom in human and animals, such as diabetes, obesity and hyperlipemia.

Abstract: A novel 1,2-dithiol-3-thione derivative which has an immunomodulating property, which is expressed by the formula (I): ##STR1## wherein R denotes hydrogen, halogen, lower alkoxy group, lower alkyl group, amino group, lower alkyl-substituted amino group or lower alkoxycarbonyl group.

Abstract: Cyclohexane-1,3-dione derivatives of the formula ##STR1## where A is an unsubstituted or substituted, saturated or unsaturated 4-membered to 7-membered ring which contains 1 or 2 sulfinyl or sulfonyl groups, R.sup.1 is hydrogen, methoxycarbonyl, ethoxycarbonyl, methyl or cyano, R.sup.2 is alkyl and R.sup.3 is alkyl, alkenyl, haloalkenyl or propargyl, and salts of these compounds are used for controlling undesirable plant growth.

Abstract: A novel charge transfer complex of an N,N'-biscyanoquinone bisimine of the formula ##STR1## and a fulvalene derivative of the formula ##STR2## where, in formula I, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently of one another are --H, --CH.sub.3, --C.sub.2 H.sub.5, --OCH.sub.3, --OC.sub.2 H.sub.5, --Cl and/or --Br, and one of the radicals R.sup.1 and R.sup.2 and/or one of the radicals R.sup.3 and R.sup.4 may furthermore be phenyl or tert.-butyl, or R.sup.1 and R.sup.2 and/or R.sup.3 and R.sup.4 together form ##STR3## and the fused-on aromatic ring is unsubstituted or substituted, and, in formula (II), R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently of one another are each --H, --CH.sub.3, --C.sub.2 H.sub.5, phenyl, methylphenyl or methoxyphenyl, or R.sup.5 and R.sup.6 and/or R.sup.7 and R.sup.8 together form ##STR4## where n=3, 4 or 5, ##STR5## and X and Y indendently of one another are each S or Se.

Abstract: There is provided a new class of derivatives of 2-nitro-5-(substituted-phenoxy) benzoyl compounds that have pre- and post-emergence herbicidal activity. The derivatives include certain substituted phenyl esters, phenyl thioesters; heterocyclic esters; substituted alkyl and alkylthio esters; carbonates and thiocarbonates; benzoyl phosphonates; substituted alkanones and substituted amides.

Abstract: This invention relates to novel compounds useful as intermediates in the preparation of cephalosporin compounds of antibacterial activity, having the formula ##STR1## wherein R.sup.1 is a group of the formula ##STR2## in which X is sulfur, oxygen or substituted or unsubstituted imino, andR.sup.2 is hydrogen or a saturated or unsaturated aliphatic hydrocarbon residue,a derivative at the carboxy group thereof and salt thereof.

Abstract: Bis-sulfenylated bis-carbamate compounds exhibit activity against insect and mite pests.

Abstract: Sulfur-containing bis-amino carbamate compounds exhibit outstanding acaricidal, nematocidal and insecticidal activity.

Abstract: Bis-sulfenylated bis-carbamate compounds exhibit activity against insect and mite pests.

Abstract: There are provided herbicidal trithione derivatives of benzoic acids.

Abstract: Derivatives of 1,2,3,4-tetrahydro-1,4-methanonaphthalene, and the use of h compounds to control viral infections, particularly influenza virus, in warm-blooded animals are disclosed. Pharmaceutical compositions containing an antiviral effective amount of the novel compounds and a pharmaceutically acceptable carrier are also disclosed.